@misc{oai:repo.qst.go.jp:00075572,
 author = {Watanabe, Shigeki and Mohammad, Anwar-Ul Azim and Nishinaka, Ichiro and Sasaki, Ichiro and Oshima, Yasuhiro and Yamada, Keiichi and Ishioka, Noriko and Watanabe, Shigeki and Nishinaka, Ichiro and Sasaki, Ichiro and Oshima, Yasuhiro and Ishioka, Noriko},
 month = {Apr},
 note = {The astatine-211 (At-211) labeled compound, 4-[211At]astato-L-phenylalanine, is one of the most promising amino acid derivatives for use in targeted alpha therapy (TAT) for various cancers. Electrophilic demetallation of stannyl precursor is the most widely used approach for labeling biomolecules with At-211. However, the low acid-resistance of the stannyl precursor necessitates the use of a N- and C- terminus protected precursor, which causes low overall radiochemical yield (RCY) due to the multiple synthetic steps involved. A deprotected organosilyl compound, 4-triethylsilylphenylalanine, was employed for direct synthesis of the astatinated phenylalanine in this study., 11th International Symposium on Targeted-Alpha-Therapy (TAT11)},
 title = {Synthesis of 4-[211At]astato-L-phenylalanine via electrophilic demetallation from a silyl precursor},
 year = {2019}
}